This book deals with the essential factors in the personalization of treatment for primary breast cancer. These include host issues, lymph node surgery, radiation therapy and preoperative systemic treatment requiring specialized knowledge, multidisciplinary care experience, techniques, and research. Locoregional treatment in conjunction with systemic treatments is another important factor, with options for local therapy significantly affected by genetic BRCA mutation. Axillary treatment issues have become top priorities in recent primary breast cancer care and these are highlighted in the book’s presentation of technological advances in lymph node mapping and diagnosis, axillary clearance in patients with nodal metastasis and the role of axillary surgery. Attention is also given to locoregional treatment after preoperative systemic therapy. Because therapeutic impact differs depending upon biological characteristics such as tumor subtype, local therapy should be based both on tumor biology and on therapeutic response in parallel. Associated translational research and mathematical prediction tools such as nomograms also are introduced. This book provides the essence of primary breast cancer care, particularly its individualization with novel therapeutic concepts and strategies and will greatly benefit physicians and clinical investigators in breast cancer institutions. Table of Contents Part 1.- Treatment for the patients having breast cancer high-risk 1.- Treatment of the patients having genetic disorders 2.- BRCA associated increased risk for breast cancer in Australia 3.- Risk reducing surgery for breast cancer patients having BRCA mutation 4.- Risk reducing surgery for females having BRCA mutation
Part 2.- Axillary treatment 5.- Sentinel lymph node biopsy and neoadjuvant chemotherapy in primary breast cancer 6.- Axillary Reverse Mapping 7.- Role of ultrasound in axillary staging 8.- One Step Nucleic acid Amplification (OSNA) Assay for primary breast cancer 9.- Management of the clinically node-negative axilla in primary breast cancer 10.- Lymphatic mapping and optimization of sentinel nodes dissection Part 3.- Radiation therapy 11.- Personalisation of radiotherapy for breast cancer 12.- Advances in Radiation therapy 13.- The role of radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer Part 4.- Preoperative hormone therapy 14.- Translational research of neoadjuvant endocrine therapy 15.- Alternation of biomarkers in tumor microenviroment by neoadjuvant endocrine therapy 16.- Exploration of host factors affecting endocrine therapy response 17.- Surgical management after preoperative hormone therapy Part 5.- Preoperative chemotherapy 18.- Neoadjuvant systemic chemotherapy 19.- The challenge to overcome TNBC heterogeneity 20.- Surgical management of breast after preoperative systemic treatment 21.- Assessment of tumor response by preoperative systemic treatment Part 6.- Preoperative anti-HER2 therapy 22.- ERBB2-targeting therapy updates 23.- Preoperative Therapy for HER2-Positive Breast Cancer 24.- Locoregional Therapy Following Neoadjuvant Therapy for HER2 Positive Breast Cancer: Opportunities and Challenges Part 7.- Mathematical prediction/assessment model 25.- Nomograms to predict positive resection margin and to predict 3 or more positive lymph nodes 26.- Individualized breast cancer care using nomograms 27.- Data mining and mathematical models development. Authors Masakazu Toi, Professor, Breast Surgery, Kyoto University Eric P Winer, Professor, Department of Medicine, Harvard Medical School John R Benson, Professor, Cambridge Breast Unit, Cambridge University Suzanne Klimberg, Breast Surgical Oncology, University of Arkansas for Medical Sciences.